| |
| |
| Exchange: |
American Stock Exchange |
| Security
Type: |
Common |
| Shares
Out: |
3,971,000 |
| Market
Cap: |
264.87(K) |
| Last
Volume: |
1,039,421 |
Avg
Vol: |
1,036,547 |
| 52
Week Range: |
$0.0667 - $0.0667 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Palisade Bio is a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing innovative oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract. Co.'s lead therapeutic candidate, LB1148, is an oral liquid formulation of the well-characterized digestive enzyme inhibitor, tranexamic acid, intended to inhibit digestive enzyme activity and preserve gut integrity during intestinal stress resulting from, among other things, reduced blood flow to the intestine, infections, or due to surgery.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
30,000 |
80,000 |
246,831 |
| Total Buy Value |
$0 |
$16,332 |
$45,045 |
$84,020 |
| Total People Bought |
0 |
2 |
2 |
3 |
| Total Buy Transactions |
0 |
3 |
6 |
10 |
| Total Shares Sold |
0 |
0 |
300 |
300 |
| Total Sell Value |
$0 |
$0 |
$192 |
$192 |
| Total People Sold |
0 |
0 |
1 |
1 |
| Total Sell Transactions |
0 |
0 |
1 |
1 |
| End Date |
2024-02-11 |
2023-11-10 |
2023-05-12 |
2022-05-12 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Garr Richard |
CEO |
• • – |
2013-02-25 |
4 |
S |
$1.15 |
$13,800 |
I/I |
(12,000) |
213,000 |
|
- |
|
| Johe Karl |
Chief Scientific Officer |
• • – |
2013-02-20 |
4 |
AS |
$1.18 |
$15,104 |
D/D |
(12,800) |
808,994 |
|
- |
|
| Johe Karl |
Chief Scientific Officer |
• • – |
2013-01-22 |
4 |
AS |
$1.27 |
$16,256 |
D/D |
(12,800) |
821,794 |
|
- |
|
| Johe Karl |
Chief Scientific Officer |
• • – |
2012-12-20 |
4 |
AS |
$1.16 |
$14,822 |
D/D |
(12,800) |
834,594 |
|
- |
|
| Johe Karl |
Chief Scientific Officer |
• • – |
2012-11-20 |
4 |
AS |
$1.00 |
$12,800 |
D/D |
(12,800) |
847,394 |
|
- |
|
| Garr Richard |
CEO |
• • – |
2012-07-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
3,000 |
1,278,327 |
|
- |
|
| Garr Richard |
CEO |
• • – |
2012-07-22 |
4 |
D |
$0.00 |
$0 |
D/D |
(120,821) |
1,281,327 |
|
- |
|
| Garr Richard |
CEO |
• • – |
2012-06-20 |
4 |
GD |
$0.00 |
$0 |
D/D |
28,000 |
1,374,148 |
|
- |
|
| Johe Karl |
Chief Scientific Officer |
• • – |
2012-06-18 |
4 |
D |
$0.00 |
$0 |
D/D |
(256,790) |
860,194 |
|
- |
|
| Johe Karl |
Chief Scientific Officer |
• • – |
2011-11-14 |
4 |
D |
$0.00 |
$0 |
D/D |
(745,000) |
1,126,984 |
|
- |
|
| Westreich Stanley |
Director |
– • – |
2011-02-15 |
3/A |
IO |
$0.00 |
$0 |
I/I |
0 |
1,457,902 |
|
- |
|
| Garr Richard |
CEO |
• • – |
2011-01-28 |
4/A |
A |
$0.00 |
$0 |
D/D |
19,802 |
1,588,072 |
|
- |
|
| Conron John |
Chief Financial Officer |
• – – |
2011-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
18,565 |
115,492 |
|
- |
|
| Garr Richard |
CEO |
• • – |
2011-01-28 |
4 |
A |
$0.00 |
$0 |
D/D |
19,802 |
1,588,072 |
|
- |
|
| Westreich Stanley |
Director |
– • – |
2011-01-15 |
3 |
IO |
$0.00 |
$0 |
I/I |
0 |
1,457,902 |
|
- |
|
| Garr Richard |
CEO |
• • – |
2010-12-27 |
4 |
GD |
$0.00 |
$0 |
D/D |
60,000 |
1,568,270 |
|
- |
|
| Ogilvie Scott Varde |
Director |
– • – |
2010-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
15,000 |
|
- |
|
| Oldaker William Clyde |
Director |
– • – |
2010-11-15 |
4 |
A |
$0.00 |
$0 |
D/D |
15,000 |
104,300 |
|
- |
|
| Johe Karl |
Chief Scientific Officer |
• • – |
2010-11-11 |
4 |
A |
$0.00 |
$0 |
D/D |
143,247 |
1,871,984 |
|
- |
|
| Garr Richard |
CEO |
• – – |
2010-11-11 |
4 |
A |
$0.00 |
$0 |
D/D |
138,122 |
1,628,270 |
|
- |
|
| Conron John |
Chief Financial Officer |
• – – |
2010-11-11 |
4 |
A |
$0.00 |
$0 |
D/D |
34,615 |
96,927 |
|
- |
|
| Oldaker William Clyde |
Director |
– • – |
2010-09-16 |
4 |
B |
$2.31 |
$23,175 |
D/D |
10,000 |
89,300 |
2.39 |
- |
|
| Johe Karl |
Chief Scientific Officer |
• • – |
2010-07-08 |
4 |
A |
$0.00 |
$0 |
D/D |
33,253 |
1,728,737 |
|
- |
|
| Conron John |
Chief Financial Officer |
• – – |
2010-07-08 |
4 |
A |
$0.00 |
$0 |
D/D |
10,948 |
62,312 |
|
- |
|
| Garr Richard |
CEO |
• – – |
2010-07-08 |
4 |
A |
$0.00 |
$0 |
D/D |
76,953 |
1,490,148 |
|
- |
|
206 Records found
|
|
Page 7 of 9 |
|
|
